grepcent public filings, reorganized for comparison

TENET HEALTHCARE CORP (THC)

CIK: 0000070318. SIC: 8062 Services-General Medical & Surgical Hospitals, NEC. Latest 10-K as of: 2026-02-17.

SIC breadcrumb: Services > SIC Major Group 80 > SIC 8062 Services-General Medical & Surgical Hospitals, NEC

SEC company page: https://www.sec.gov/edgar/browse/?CIK=70318. Latest filing source: 0000070318-26-000012.

Informational only. Descriptive public-record data — not a rating, forecast, or investment advice. See Disclaimer.

At a glance

FY2025 · period end 2025-12-31 · filed 2026-02-17 · accession 0000070318-26-000012 · source: SEC companyfacts

Revenue
21,310,000,000 USD verified
Net income
2,367,000,000 USD verified
Assets
29,677,000,000 USD verified
Free cash flow
2,530,000,000 USD computed
Net margin
11.11% computed
Operating margin
16.46% computed
Revenue YoY
+3.07% computed
ROE
56.09% computed

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

Peer & cluster context

Peer percentile fingerprint

THC ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC major-group 80; per-ratio N printed.THC ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC major-group 80; per-ratio N printed.RatioTHCPeer medianPercentileNNet margin11.1%3.2%9556Operating margin16.5%5.5%9451Revenue growth3.1%11.8%2057FCF margin11.9%5.4%8748ROE56.1%7.9%9653ROA8.0%2.8%8658Liabilities / equity4.911.138954Current ratio1.761.635458

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC major-group 80 SIC Major Group 80, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

Selected Fundamentals

MetricValueUnitFYFiled
Revenue21,310,000,000USD20252026-02-17
Net income2,367,000,000USD20252026-02-17
Assets29,677,000,000USD20252026-02-17

Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-02-17. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000070318.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

Download these verified figures (annual + quarterly, with per-value filing provenance): JSON · CSV

Flow metrics use full-year FY periods from 10-K/10-K/A filings; balance-sheet metrics use FY-end instants. Free cash flow = operating cash flow - capital expenditures. Missing metrics are omitted rather than fabricated.

Metric201320152016201720182019202020212022202320242025
Revenue21,070,000,00020,613,000,00018,313,000,00018,479,000,00017,640,000,00019,485,000,00019,174,000,00020,564,000,00020,675,000,00021,310,000,000
Net income176,000,000-320,000,000459,000,000171,000,000768,000,0001,476,000,0001,001,000,0001,311,000,0004,064,000,0002,367,000,000
Operating income1,247,000,0001,113,000,0001,637,000,0001,537,000,0001,989,000,0002,871,000,0002,333,000,0002,510,000,0005,956,000,0003,508,000,000
Diluted EPS-1.93-7.001.00-2.083.758.423.795.7132.7015.49
Operating cash flow558,000,0001,200,000,0001,049,000,0001,233,000,0003,407,000,0001,568,000,0001,083,000,0002,374,000,0002,047,000,0003,540,000,000
Capital expenditures875,000,000707,000,000617,000,000670,000,000540,000,000658,000,000762,000,000751,000,000931,000,0001,010,000,000
Share buybacks400,000,00040,000,0000.000.000.000.00250,000,000200,000,000672,000,0001,386,000,000
Assets24,701,000,00023,385,000,00022,430,000,00023,365,000,00027,106,000,00027,579,000,00027,156,000,00028,312,000,00028,936,000,00029,677,000,000
Liabilities21,226,000,00020,980,000,00020,302,000,00021,422,000,00024,217,000,00023,322,000,00022,548,000,00022,804,000,00020,389,000,00020,704,000,000
Stockholders' equity417,000,000-147,000,000-119,000,000-417,000,00028,000,0001,028,000,0001,142,000,0001,608,000,0004,171,000,0004,220,000,000
Cash and cash equivalents716,000,000611,000,000411,000,000262,000,0002,446,000,0002,364,000,000858,000,0001,228,000,0003,019,000,0002,883,000,000
Free cash flow-317,000,000493,000,000432,000,000563,000,0002,867,000,000910,000,000321,000,0001,623,000,0001,116,000,0002,530,000,000

Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

Metric201320152016201720182019202020212022202320242025
Net margin0.84%-1.55%2.51%0.93%4.35%7.58%5.22%6.38%19.66%11.11%
Operating margin5.92%5.40%8.94%8.32%11.28%14.73%12.17%12.21%28.81%16.46%
Return on equity42.21%143.58%87.65%81.53%97.43%56.09%
Return on assets0.71%-1.37%2.05%0.73%2.83%5.35%3.69%4.63%14.04%7.98%
Liabilities / equity50.9022.6919.7414.184.894.91
Current ratio1.301.291.201.211.471.381.341.511.781.76

Industry Peer Context

Each number-line places THC against the min, median, and max of latest reported values among companies in the same SIC industry when at least three peers report that ratio.

Net margin peer context

THC Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8062; peer count 6.THC Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8062; peer count 6.6 SIC peersMin -2.4%Median 6.3%Max 11.1%THC 11.1%

Operating margin peer context

THC Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8062; peer count 4.THC Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8062; peer count 4.4 SIC peersMin 11.5%Median 11.8%Max 16.5%THC 16.5%

ROE peer context

THC ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8062; peer count 4.THC ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8062; peer count 4.4 SIC peersMin -4.5%Median 15.5%Max 56.1%THC 56.1%

ROA peer context

THC ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8062; peer count 6.THC ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8062; peer count 6.6 SIC peersMin -1.0%Median 5.9%Max 11.2%THC 8.0%

Financial Bridges

Waterfall figures reconcile reported SEC companyfacts components. Missing bridges are omitted when required components are not present for the same fiscal year.

Free cash flow = operating cash flow - capital expenditures

THC FY2025 free cash flow bridge from reported figures.THC FY2025 free cash flow bridge from reported figures.THC free cash flow bridgeFY2025: operating cash flow less capital expendituresSource: SEC companyfacts FY2025.Free cash flow bridgeReported amount$0.0B$2.0B$4.0B$3.5BOperating cash flow-$1.0BCapex$2.5BFree cash flow

Figure provenance: SEC companyfacts FY 2025. Operating cash flow: accession 0000070318-26-000012; concept NetCashProvidedByUsedInOperatingActivities; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities | Capital expenditures: accession 0000070318-26-000012; concept PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | Free cash flow: accession 0000070318-26-000012; concept NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

Financial Charts

THC revenue, last 5 periods. Source: SEC companyfacts FY2025.THC revenue, last 5 periods. Source: SEC companyfacts FY2025.THC RevenueLatest point: FY2025 = $21.3BSource: SEC companyfacts FY2025.Fiscal yearReported revenue$0.0B$15.0B$30.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000070318-26-000012; filed 2026-02-17. Concept: RevenueFromContractWithCustomerExcludingAssessedTax. Source concepts: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

THC net income, last 5 periods. Source: SEC companyfacts FY2025.THC net income, last 5 periods. Source: SEC companyfacts FY2025.THC Net incomeLatest point: FY2025 = $2.4BSource: SEC companyfacts FY2025.Fiscal yearNet income$0.0B$3.0B$6.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000070318-26-000012; filed 2026-02-17. Concept: ProfitLoss. Source concepts: us-gaap:ProfitLoss.

THC operating income, last 5 periods. Source: SEC companyfacts FY2025.THC operating income, last 5 periods. Source: SEC companyfacts FY2025.THC Operating incomeLatest point: FY2025 = $3.5BSource: SEC companyfacts FY2025.Fiscal yearOperating income$0.0B$3.0B$6.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000070318-26-000012; filed 2026-02-17. Concept: OperatingIncomeLoss. Source concepts: us-gaap:OperatingIncomeLoss.

THC diluted eps, last 5 periods. Source: SEC companyfacts FY2025.THC diluted eps, last 5 periods. Source: SEC companyfacts FY2025.THC Diluted EPSLatest point: FY2025 = $15.49/shareSource: SEC companyfacts FY2025.Fiscal yearDiluted EPS (USD/share)$0.00/share$20.00/share$40.00/shareFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000070318-26-000012; filed 2026-02-17. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

THC operating cash flow, last 5 periods. Source: SEC companyfacts FY2025.THC operating cash flow, last 5 periods. Source: SEC companyfacts FY2025.THC Operating cash flowLatest point: FY2025 = $3.5BSource: SEC companyfacts FY2025.Fiscal yearOperating cash flow$0.0B$2.0B$4.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000070318-26-000012; filed 2026-02-17. Concept: NetCashProvidedByUsedInOperatingActivities. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities.

THC capital expenditures, last 5 periods. Source: SEC companyfacts FY2025.THC capital expenditures, last 5 periods. Source: SEC companyfacts FY2025.THC Capital expendituresLatest point: FY2025 = $1.0BSource: SEC companyfacts FY2025.Fiscal yearCapital expenditures$0.0B$1.0B$2.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000070318-26-000012; filed 2026-02-17. Concept: PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

THC share buybacks, last 5 periods. Source: SEC companyfacts FY2025.THC share buybacks, last 5 periods. Source: SEC companyfacts FY2025.THC Share buybacksLatest point: FY2025 = $1.4BSource: SEC companyfacts FY2025.Fiscal yearShare buybacks$0.0B$1.0B$2.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000070318-26-000012; filed 2026-02-17. Concept: PaymentsForRepurchaseOfCommonStock. Source concepts: us-gaap:PaymentsForRepurchaseOfCommonStock.

THC assets, last 5 periods. Source: SEC companyfacts FY2025.THC assets, last 5 periods. Source: SEC companyfacts FY2025.THC AssetsLatest point: FY2025 = $29.7BSource: SEC companyfacts FY2025.Fiscal yearAssets$0.0B$15.0B$30.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000070318-26-000012; filed 2026-02-17. Concept: Assets. Source concepts: us-gaap:Assets.

THC liabilities, last 5 periods. Source: SEC companyfacts FY2025.THC liabilities, last 5 periods. Source: SEC companyfacts FY2025.THC LiabilitiesLatest point: FY2025 = $20.7BSource: SEC companyfacts FY2025.Fiscal yearLiabilities$0.0B$15.0B$30.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000070318-26-000012; filed 2026-02-17. Concept: Liabilities. Source concepts: us-gaap:Liabilities.

THC stockholders' equity, last 5 periods. Source: SEC companyfacts FY2025.THC stockholders' equity, last 5 periods. Source: SEC companyfacts FY2025.THC Stockholders' equityLatest point: FY2025 = $4.2BSource: SEC companyfacts FY2025.Fiscal yearStockholders' equity$0.0B$3.0B$6.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000070318-26-000012; filed 2026-02-17. Concept: StockholdersEquity. Source concepts: us-gaap:StockholdersEquity.

THC cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2025.THC cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2025.THC Cash and cash equivalentsLatest point: FY2025 = $2.9BSource: SEC companyfacts FY2025.Fiscal yearCash and cash equivalents$0.0B$2.0B$4.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000070318-26-000012; filed 2026-02-17. Concept: CashAndCashEquivalentsAtCarryingValue. Source concepts: us-gaap:CashAndCashEquivalentsAtCarryingValue.

THC free cash flow, last 5 periods. Source: SEC companyfacts FY2025.THC free cash flow, last 5 periods. Source: SEC companyfacts FY2025.THC Free cash flowLatest point: FY2025 = $2.5BSource: SEC companyfacts FY2025.Fiscal yearFree cash flow$0.0B$2.0B$4.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000070318-26-000012; filed 2026-02-17. Concept: NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

As-reported value updates

5 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period.

View the filing-by-filing ledger →

Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-07-29. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000070318.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

QuarterEnd DateRevenueNet IncomeDiluted EPSMethod
2022-Q32022-09-301.16reported discrete quarter
2023-Q12023-03-311.32reported discrete quarter
2023-Q22023-06-301.15reported discrete quarter
2023-Q32023-09-305,066,000,000266,000,0000.94reported discrete quarter
2023-Q42023-12-315,379,000,000456,000,000derived Q4 = FY annual - nine-month YTD
2024-Q12024-03-315,368,000,0002,334,000,00021.38reported discrete quarter
2024-Q22024-06-305,103,000,000477,000,0002.64reported discrete quarter
2024-Q32024-09-305,122,000,000681,000,0004.89reported discrete quarter
2024-Q42024-12-315,072,000,000572,000,000derived Q4 = FY annual - nine-month YTD
2025-Q12025-03-315,223,000,000622,000,0004.27reported discrete quarter
2025-Q22025-06-305,271,000,000522,000,0003.14reported discrete quarter
2025-Q32025-09-305,289,000,000579,000,0003.86reported discrete quarter
2025-Q42025-12-315,527,000,000644,000,000derived Q4 = FY annual - nine-month YTD
2026-Q12026-03-315,368,000,000906,000,0008.01reported discrete quarter
2026-Q22026-06-305,628,000,0001,045,000,0009.84reported discrete quarter

Quarterly Charts

THC quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q2.THC quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q2.THC Quarterly RevenueLatest point: 2026-Q2 = $5.6BSource: SEC companyfacts 2026-Q2.Fiscal quarterQuarterly Revenue$0.0B$3.0B$6.0B2023-Q32023-Q42024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q2

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0000070318-26-000037; filed 2026-07-29. Concept: RevenueFromContractWithCustomerExcludingAssessedTax. Source concepts: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

THC quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q2.THC quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q2.THC Quarterly Net incomeLatest point: 2026-Q2 = $1.0BSource: SEC companyfacts 2026-Q2.Fiscal quarterQuarterly Net income$0.0B$2.0B$4.0B2023-Q32023-Q42024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q2

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0000070318-26-000037; filed 2026-07-29. Concept: ProfitLoss. Source concepts: us-gaap:ProfitLoss.

THC quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q2.THC quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q2.THC Quarterly Diluted EPSLatest point: 2026-Q2 = $9.84/shareSource: SEC companyfacts 2026-Q2.Fiscal quarterQuarterly Diluted EPS (USD/share)$0.00/share$12.50/share$25.00/share2022-Q32023-Q12023-Q22023-Q32024-Q12024-Q22024-Q32025-Q12025-Q22025-Q32026-Q12026-Q2

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0000070318-26-000037; filed 2026-07-29. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

Business

Read THC's verbatim Item 1 Business section from its latest 10-K: Business.

Risk Factors

Read THC's verbatim Item 1A Risk Factors from its latest 10-K: Risk Factors.

Latest quarter (10-Q)

Latest 10-Q source: 0000070318-26-000037.

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Confidence: high. Filing date: 2026-07-29. Report date: 2026-06-30.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

INTRODUCTION TO MANAGEMENT’S DISCUSSION AND ANALYSIS

The purpose of this section, Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”), is to provide a narrative explanation of our financial statements that enables investors to better understand our business, to enhance our overall financial disclosures, to give context to the analysis of our financial information, and to provide information about the quality of, and potential variability of, our financial condition, results of operations and cash flows. MD&A, which should be read in conjunction with the accompanying Condensed Consolidated Financial Statements, includes the following sections:

•Management Overview

•Forward-Looking Statements

•Sources of Revenue for Our Hospital Operations Segment

•Results of Operations

•Liquidity and Capital Resources

•Critical Accounting Estimates

Our business consists of our Hospital Operations and Services (“Hospital Operations”) segment and our Ambulatory Care segment. Our Hospital Operations segment is comprised of our acute care and specialty hospitals, a network of employed physicians and ancillary outpatient facilities. At June 30, 2026, our subsidiaries operated 50 hospitals serving primarily urban and suburban communities in eight states. Our Hospital Operations segment also included 135 outpatient facilities, including urgent care centers, imaging centers, off-campus hospital emergency departments and micro‑hospitals, at June 30, 2026. In addition, our Hospital Operations segment provides revenue cycle management and value-based care services to hospitals and other healthcare facilities, health systems, physician practices, employers and other clients through Conifer Health Solutions, LLC (“Conifer”).

Our Ambulatory Care segment, through USPI Holding Company, Inc. (together with its subsidiaries, “USPI”), held ownership interests in 538 ambulatory surgery centers (each, an “ASC”), 405 of which are consolidated, and 26 surgical hospitals, eight of which are consolidated, in 37 states at June 30, 2026. USPI’s facilities offer a range of procedures and service lines, including, among other specialties: orthopedics, total joint replacement, and spinal and other musculoskeletal procedures; gastroenterology; pain management; otolaryngology (ear, nose and throat); ophthalmology; and urology.

Unless otherwise indicated, all financial and statistical information included in MD&A relates to our continuing operations, with dollar amounts expressed in millions (except per adjusted admission and per adjusted patient day amounts). Continuing operations information includes the results of all facilities operated during any portion of the periods presented, and it reflects the performance of those facilities only for the time periods in which we operated them. Continuing operations information excludes the results of our hospitals and other businesses classified as discontinued operations for accounting purposes. We believe this presentation is useful to investors because continuing operations information reflects the impact of the addition or disposition of individual hospitals and other operations on our volumes, revenues and expenses.

In certain cases, information presented in MD&A for our Hospital Operations segment is described as presented on a same‑hospital basis, which includes facilities we operated for the entirety of the periods presented. For the six-month periods ended June 30, 2026 and 2025, information presented on a same‑hospital basis includes the results of our same 49 hospitals and those outpatient centers we operated throughout both periods, and excludes the results of: Florida Coast Medical Center, the acute care hospital we opened in Florida in September 2025; businesses classified as discontinued operations for accounting purposes during those periods; and other ancillary facilities acquired or divested during the reporting periods that have a limited financial or operational impact. We present same‑hospital data because we believe it provides investors with useful information regarding the performance of our current portfolio of hospitals and other operations that are comparable for the periods presented. Furthermore, same‑hospital data may more clearly reflect recent trends we are experiencing with respect to volumes, revenues and expenses exclusive of variations caused by the addition or disposition of individual hospitals and other operations.

Our Ambulatory Care segment reports growth data on a same-facility systemwide basis, which includes both consolidated and unconsolidated facilities held at the end of the period, as well as facilities acquired during the period on a pro forma basis as if owned for the full period. Divested facilities are generally excluded; however, management may include facilities sold near the end of the period when, in its judgment, their inclusion provides financial statement users with a better understanding of the segment’s performance. This approach offers insights into the performance of our current portfolio by excluding variations from facility acquisitions or dispositions. Although we do not record the revenues of unconsolidated

22

Table of Contents

facilities, this information is important for understanding the financial performance of our Ambulatory Care segment, as these revenues form the basis for calculating management services revenues and equity in earnings of unconsolidated affiliates. Additionally, this presentation enhances comparability across periods.

We present certain operational metrics and statistics in order to provide additional insight into our operational performance efficiency and to help investors better understand management’s view and strategic focus. We define these operational metrics and statistics as follows:

Adjusted admissions—represents actual admissions in the period adjusted to include outpatient services provided by facilities in our Hospital Operations segment by multiplying actual admissions by the sum of gross inpatient revenues and outpatient revenues and dividing the result by gross inpatient revenues;

Adjusted patient days—represents actual patient days in the period adjusted to include outpatient services provided by facilities in our Hospital Operations segment by multiplying actual patient days by the sum of gross inpatient revenues and outpatient revenues and dividing the result by gross inpatient revenues; and

Utilization of licensed beds—represents patient days divided by the number of days in the period divided by average licensed beds.

We also present certain metrics as a percentage of net operating revenues because a significant portion of our operating expenses are variable, and we present certain metrics on a per adjusted admission and per adjusted patient day basis to show trends other than volume.

MANAGEMENT OVERVIEW

OPERATING ENVIRONMENT AND TRENDS

In the Management Overview section of MD&A in our Annual Report on Form 10-K for the year ended December 31, 2025 (“Annual Report”), we described several key trends that continue to impact the healthcare industry, along with other factors affecting our business environment and operations, including the potential impact of changes in federal and state healthcare laws, regulations, funding policies and reimbursement practices. We continue to monitor developments affecting Medicaid funding, health insurance marketplace enrollment and payer mix, as well as the influence of geopolitical dynamics, trade tensions, tariffs and export control rules on pricing and availability within global supply chains. These challenges underscore the importance of operational discipline and adaptive cost management as we navigate the evolving healthcare landscape.

STRATEGIES

Expanding Our Ambulatory Care Segment—We continue to focus on opportunities to expand our Ambulatory Care segment through acquisitions, organic growth in our physician relationships and service lines, construction of new outpatient centers and strategic partnerships. We believe USPI’s ASCs and surgical hospitals offer many advantages to patients and physicians, including greater affordability, predictability, flexibility and convenience. Moreover, due in part to advancements in surgical techniques, medical technology and anesthesia, as well as the lower cost structure and greater efficiencies that are attainable at a specialized outpatient site, we believe the volume and complexity of surgical cases performed in an outpatient setting will continue to increase over time. Historically, our outpatient services have generated significantly higher margins for us than inpatient services.

Driving Growth in Our Hospital Operations Segment—We remain committed to better positioning our hospitals and competing more effectively in the ever‑evolving healthcare environment by focusing on driving performance through operational effectiveness, investing in our physician enterprise, particularly our specialist network, enhancing patient and physician satisfaction, growing our higher‑demand clinical service lines, expanding patient and physician access, and optimizing our portfolio of assets. We believe our efforts in these areas improve the quality of care we deliver and enhance growth.

Improving the Customer Care Experience—As consumers continue to become more engaged in managing their health, we recognize that understanding what matters most to them and earning their loyalty is imperative to our success. As such, we have enhanced our focus on treating our patients as traditional customers by: (1) establishing networks of physicians and facilities that provide convenient access to services across the care continuum; (2) expanding service lines aligned with growing community demand, including a focus on aging and chronic disease patients; (3) offering greater affordability and predictability, including simplified registration and discharge procedures, particularly in our outpatient centers; (4) improving our culture of service; and (5) offering health programs and educational materials tailored to meet the needs of the communities we serve.

23

Table of Contents

Recent advancements in technology and applications in healthcare have allowed us to accelerate the adoption of artificial intelligence (“AI”) and Generative AI-enabled tools in areas such as clinical care coordination, medical documentation, revenue cycle management and administrative services. When used responsibly, we believe AI has the potential to enhance our business processes and support efficient delivery of high‑quality care.

Improving Profitability—We continue to focus on growing patient volumes and effective cost management as a means to improve profitability. We believe that emphasis on higher‑demand clinical service lines, focus on expanding our ambulatory care business, cultivation of our culture of service and utilization of contracting strategies that create shared value with payers should help us grow our patient volumes over time. We are also continuing to pursue new opportunities to enhance efficiency, including further integration of enterprise‑wide centralized support functions, outsourcing additional functions unrelated to direct patient care and reducing clinical contract variation.

Managing Our Capital Structure—All of our long‑term debt has a fixed rate of interest, except for outstanding borrowings under our senior secured revolving credit facility (the “Credit Agreement”), of which we had none at June 30, 2026. In addition, the maturity dates of our notes are staggered from 2027 through 2033. We believe that our capital structure helps to minimize the near‑term impact of increases in interest rates, and the staggered maturities of our debt allow us to retire or refinance our debt over time.

In the six months ended June 30, 2026, we repurchased 7.021 mill

[Excerpt truncated for page length; source filing is linked above.]

Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: 0000070318-26-000012. The complete FY 2025 MD&A is published at /company/THC/mda/fy2025/.

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Confidence: high. Filing date: 2026-02-17. Report date: 2025-12-31.

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

INTRODUCTION TO MANAGEMENT’S DISCUSSION AND ANALYSIS

The purpose of this section, Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”), is to provide a narrative explanation of our financial statements that enables investors to better understand our business, to enhance our overall financial disclosures, to give context to the analysis of our financial information, and to provide information about the quality of, and potential variability of, our financial condition, results of operations and cash flows. MD&A, which should be read in conjunction with the accompanying Consolidated Financial Statements, includes the following sections:

•Management Overview

•Sources of Revenue for Our Hospital Operations and Services Segment

•Results of Operations

•Liquidity and Capital Resources

•Recently Issued Accounting Standards

•Critical Accounting Estimates

Our business consists of our Hospital Operations and Services (“Hospital Operations”) segment and our Ambulatory Care segment. Our Hospital Operations segment is comprised of our acute care and specialty hospitals, a network of employed physicians and ancillary outpatient facilities. At December 31, 2025, our subsidiaries operated 50 hospitals serving primarily urban and suburban communities in eight states. Our Hospital Operations segment also included 132 outpatient facilities, namely urgent care centers, imaging centers, off-campus hospital emergency departments and micro‑hospitals, at December 31, 2025. In addition, our Hospital Operations segment provides revenue cycle management and value‑based care services to hospitals, health systems, physician practices, employers and other clients through Conifer Health Solutions, LLC.

Our Ambulatory Care segment, through USPI Holding Company, Inc. (together with its subsidiaries, “USPI”), held ownership interests in 533 ambulatory surgery centers (each, an “ASC”), 401 of which are consolidated, and 26 surgical hospitals, eight of which are consolidated, in 37 states at December 31, 2025. USPI’s facilities offer a range of procedures and service lines, including, among other specialties: orthopedics, total joint replacement, and spinal and other musculoskeletal procedures; gastroenterology; pain management; otolaryngology (ear, nose and throat); ophthalmology; and urology.

Unless otherwise indicated, all financial and statistical information included in MD&A relates to our continuing operations, with dollar amounts expressed in millions (except per adjusted admission and per adjusted patient day amounts). Continuing operations information includes the results of all facilities operated during any portion of the periods presented, and it reflects the performance of those facilities only for the time periods in which we operated them. Continuing operations information excludes the results of our hospitals and other businesses classified as discontinued operations for accounting purposes. We believe this presentation is useful to investors because continuing operations information reflects the impact of the addition or disposition of individual hospitals and other operations on our volumes, revenues and expenses.

In certain cases, information presented in MD&A for our Hospital Operations segment is described as presented on a same‑hospital basis, which includes facilities we operated for the entirety of the periods presented. For the years ended December 31, 2025 and 2024, information presented on a same-hospital basis includes the results of our same 47 hospitals and those outpatient centers we operated throughout both years, and excludes the results of: (1) three hospitals located in South Carolina and certain related operations (the “SC Hospitals”) we sold in January 2024; (2) four hospitals and certain related operations located in Orange County and Los Angeles County, California (the “OCLA CA Hospitals”) we sold in March 2024; (3) two hospitals and certain related operations located in San Luis Obispo County, California (the “Central CA Hospitals”), which we also sold in March 2024; (4) Westover Hills Baptist Hospital, the acute care hospital we opened in Texas in July 2024; (5) a rehabilitation hospital in El Paso, Texas, in which we acquired a majority ownership interest in September 2024; (6) five hospitals and certain related operations located in Alabama we divested in September 2024 (the “AL Hospitals” and, together with the SC Hospitals, OCLA CA Hospitals and Central CA Hospitals, the “Divested Hospitals”); (7) Florida Coast Medical Center, the acute care hospital we opened in Florida in September 2025; and (8) businesses classified as discontinued operations for accounting purposes during those periods, along with other ancillary facilities acquired or divested during the reporting periods that have a limited financial or operational impact. We present same‑hospital data because we believe it provides investors with useful information regarding the performance of our current portfolio of hospitals and other operations that are comparable for the periods presented. Furthermore, same‑hospital data may more clearly reflect recent

33

Table of Contents

trends we are experiencing with respect to volumes, revenues and expenses exclusive of variations caused by the addition or disposition of individual hospitals and other operations.

Our Ambulatory Care segment reports growth data on a same-facility systemwide basis, which includes both consolidated and unconsolidated facilities held at the end of the period, as well as facilities acquired during the period on a pro forma basis as if owned for the full period. Divested facilities are generally excluded; however, management may include facilities sold near the end of the period when, in its judgment, their inclusion provides financial statement users with a better understanding of the segment’s performance. This approach offers insights into the performance of our current portfolio by excluding variations from facility acquisitions or dispositions. Although we do not record the revenues of unconsolidated facilities, this information is important for understanding the financial performance of our Ambulatory Care segment, as these revenues form the basis for calculating management services revenues and equity in earnings of unconsolidated affiliates. Additionally, this presentation enhances comparability across periods.

We present certain operational metrics and statistics in order to provide additional insight into our operational performance efficiency and to help investors better understand management’s view and strategic focus. We define these operational metrics and statistics as follows:

Adjusted admissions—represents actual admissions in the period adjusted to include outpatient services provided by facilities in our Hospital Operations segment by multiplying actual admissions by the sum of gross inpatient revenues and outpatient revenues and dividing the result by gross inpatient revenues;

Adjusted patient days—represents actual patient days in the period adjusted to include outpatient services provided by facilities in our Hospital Operations segment by multiplying actual patient days by the sum of gross inpatient revenues and outpatient revenues and dividing the result by gross inpatient revenues;

Utilization of licensed beds—represents patient days divided by the number of days in the period divided by average licensed beds; and

Accounts receivable days outstanding (“AR Days”)—calculated as our accounts receivable on the last date in the quarter divided by our net operating revenues for the quarter ended on that date divided by the number of days in the quarter. This calculation includes our Hospital Operations segment’s contract assets and excludes our California provider fee program revenues and activity related to our divested facilities.

We also present certain metrics as a percentage of net operating revenues because a significant portion of our operating expenses are variable, and we present certain metrics on a per adjusted admission and per adjusted patient day basis to show trends other than volume.

MANAGEMENT OVERVIEW

RECENT DEVELOPMENT

On January 27, 2026, we entered into an agreement with CommonSpirit Health (a successor to Catholic Health Initiatives) (“CHI”) relating to Conifer Health Solutions, LLC (“Conifer”). Subject to the terms of that agreement and other related contracts, the parties have agreed to, among other things: (1) terminate the amended and restated master services agreement pursuant to which Conifer provides end-to-end revenue cycle management services to certain CHI facilities effective as of December 31, 2026; (2) CHI’s payment to us of an aggregate amount equal to $1.900 billion in annual installments over the next three years; provided that, of such amount, $540 million was satisfied on January 27, 2026 by offsetting the $540 million due to CHI from Conifer as described in the next clause; (3) the reduction of our redeemable noncontrolling interest balance, and an increase in our additional paid-in capital balance associated with the redemption by Conifer of CHI’s minority equity interest in Conifer, in exchange for a payment by Conifer of $540 million, which redemption is effective as of January 1, 2026; and (4) the grant of mutual releases to each other in respect of potential disputes related to Conifer.

OPERATING ENVIRONMENT AND TRENDS

Industry Trends and Healthcare Policy Changes—We believe that several key trends are continuing to shape the demand for healthcare services: (1) consumers, employers and insurers are actively seeking lower‑cost solutions and better value with respect to healthcare spending; (2) patient volumes are shifting from inpatient to outpatient settings due to technological advances and demand for care that is more convenient, affordable and accessible; (3) the growing aging population requires greater chronic disease management and higher‑acuity treatment; and (4) consolidation continues across the entire healthcare sector.

34

Table of Contents

The healthcare industry remains subject to significant legislative and regulatory uncertainty. Changes in federal and state healthcare laws, regulations, funding policies or reimbursement practices – especially those involving reductions to government payment rates or access to insurance coverage – could have a material impact on our future revenues and expenses. As discussed in greater detail in the Government Programs section below, the One Big Beautiful Bill Act (“OBBBA”) enacted significant changes to, among other things, the federal tax code and U.S. healthcare policy, coverage and reimbursement systems. While the most consequential healthcare provisions are not scheduled to take effect until 2027 and thereafter, the OBBBA introduces new limitations and eligibility requirements that are expected to materially impact Medicaid funding (including supplemental payments) and enrollment, as well as the health insurance marketplace. The implementation of these requirements is subject to individual state interpretation, and we are unable to predict at this time how states will implement the various requirements of the law. In addition, the OBBBA contained significant changes to the U.S. federal tax code related to the deductibility of depreciation and business interest expense. However, these changes did not have a material impact on our tax expense for the year ended December 31, 2025.

Macroeconomic and Industry Context—The healthcare environment remains influenced by broader macroeconomic and operational factors. Our business has been impacted by inflation and its effects on salaries, wages and benefits, as well as other costs. While general inflation moderated somewhat during 2025, inflation specific to medical supply prices remained high due to current economic

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A or browse all MD&A years.

MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

Macro cross-references for THC

Indicators mapped to this company's SIC classification (industry 8062 Services-General Medical & Surgical Hospitals, NEC) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

Macro-to-micro threads including this sector: US labor market, Growth & output, Government finances, Sector employment.

All 71 macro indicators →

For LLMs & downloads

Markdown twin: /company/THC.md · JSON record: /company/THC.json · verified financials: JSON / CSV · machine TOC for the whole site: /llms.txt